Fasting-Mimicking Diet Combined With Toripalimab Plus Axitinib for Metastatic or Unresectable Renal Cell Carcinoma: A Single-Arm, Open-Label, Single-Center Clinical Trial
Latest Information Update: 03 Apr 2026
At a glance
- Drugs Axitinib (Primary) ; Toripalimab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
Most Recent Events
- 03 Apr 2026 New trial record